Merck has received antitrust clearance from the competition authorities in Germany and Austria to tender an offer for the acquisition of clinical-stage biopharmaceutical firm Acceleron Pharma.
The latest move follows a definitive agreement signed by the company for the acquisition last month.
Related: Merck To Buy Acceleron For US$11.5B
Merck, through its subsidiary, commenced a cash tender offer to acquire Acceleron’s all outstanding shares, for US$180 per share, as announced on October 12 of this year.
Merck stated, “As previously announced on 29 October 2021, the tender offer will expire at 5:00 p.m., Eastern Time, on 18 November 2021, unless further extended in accordance with the merger agreement and the applicable rules and regulations of the SEC.”
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
DOJ and FTC Introduce Website for Reporting Anti-Competitive Healthcare Practices
Apr 18, 2024 by
CPI
US Congress Advances Legislation to Compel TikTok Sale
Apr 18, 2024 by
CPI
UK Financial Sector Advocates Enhanced Regulatory Accountability
Apr 18, 2024 by
CPI
Google and All 50 States Defend $700 Million Consumer Settlement
Apr 18, 2024 by
CPI
Colorado Enacts First Law to Protect Consumer Brainwave Data
Apr 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI